Literature DB >> 32579818

Urate-Lowering Therapy and Chronic Kidney Disease Progression.

Daniel I Feig1.   

Abstract

Entities:  

Year:  2020        PMID： 32579818     DOI： 10.1056/NEJMe2015886

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  An evaluation of the roles of hematuria and uric acid in defining the prognosis of patients with IgA nephropathy.

Authors:  Ron Hogg
Journal:  Pediatr Nephrol       Date:  2021-05-13       Impact factor: 3.714

Review 2.  Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.

Authors:  Hitoshi Nishizawa; Norikazu Maeda; Iichiro Shimomura
Journal:  Hypertens Res       Date:  2022-01-19       Impact factor: 3.872

3.  The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights From a Population-Based, Propensity Score-Matched Analysis.

Authors:  Chi-Jung Tai; Chin-Chung Wu; Kun-Tai Lee; Tzyy-Guey Tseng; Hui-Chun Wang; Fang-Rong Chang; Yi-Hsin Yang
Journal:  Clin Pharmacol Ther       Date:  2021-11-17       Impact factor: 6.903

4.  The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience.

Authors:  Sami Alobaidi; Naji Dwid; Khaldoun Shikh Souk; Mohamed Cheikh; Ahmed Mandurah; Khaled Al-Khatib; Ans Ahmed; Hani Almoallim
Journal:  Int J Gen Med       Date:  2021-03-30

5.  Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.

Authors:  Seokwoo Park; Jung Pyo Lee; Dong Ki Kim; Yon Su Kim; Chun Soo Lim
Journal:  PLoS One       Date:  2022-02-28       Impact factor: 3.240

6.  Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.

Authors:  Hiroshi Kataoka; Toshio Mochizuki; Mamiko Ohara; Yuki Tsuruta; Naomi Iwasa; Rie Yoshida; Ken Tsuchiya; Kosaku Nitta; Kenjiro Kimura; Tatsuo Hosoya
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.996
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.